16 October
Moderna files FDA application for booster against Omicron variants
Moderna Inc. submitted the FDA request for a booster dose aimed at modern COVID-19 variants. The step is designed to ensure greater protection in fighting the virus.
The company claims the doses of Moderna’s booster, which are currently unrivaled on the market, ready to be dispatched in September. Only regulatory approval is needed. The vaccine is intended for adults over 18 years, designed to protect from the two dominant Omicron variants, BA.4 and BA.5.
Next week, the Centers for Disease Control and Prevention will stage a meeting. The main issue is expected to be Moderna’s booster shots.
As of August 11, the company announced a clinical trial phase. Notably, UK regulators had already approved Moderna's bivalent booster against the early Omicron variant.
Recommended
Today at 2:30 PM
Yesterday at 2:30 PM
Yesterday at 2:30 PM
Yesterday at 2:30 PM
Yesterday at 2:30 PM
Top news
16 October
15 October
14 October
6 October